Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Caris Life Sciences, Inc. (NASDAQ: CAI)
CAI Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
15.40%
Analyst Rating:
BUY
Analyst Forecast (1yr):
88.70%
CAI Stock Analysis
CAI
PE Ratio:
CAI
PEG Ratio:
CAI
Forward EPS Growth (12 month):
146.90%
CAI
PS Ratio:
4.8
CAI
PSG Ratio:
0.2
CAI
Forward Revenue Growth (12 month):
20.40%
CAI Articles
No data was found